RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+7.3%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.5B
AUM Growth
+$1.5B
(+5.6%)
Cap. Flow
+$28.6M
Cap. Flow
% of AUM
1.9%
Top 10 Holdings %
Top 10 Hldgs %
31.43%
Holding
99
New
7
Increased
28
Reduced
25
Closed
7
Top Buys
| 1 |
Boston Scientific
BSX
|
$14.6M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$12.8M |
| 3 |
Danaher
DHR
|
$11.8M |
| 4 |
Inspire Medical Systems
INSP
|
$10.7M |
| 5 |
Align Technology
ALGN
|
$9.93M |
Top Sells
| 1 |
Abbott
ABT
|
$14.9M |
| 2 |
Thermo Fisher Scientific
TMO
|
$10.6M |
| 3 |
Elevance Health
ELV
|
$10.3M |
| 4 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$8.92M |
| 5 |
Biogen
BIIB
|
$8.4M |
Sector Composition
| 1 | Healthcare | 97.82% |
| 2 | Industrials | 1.29% |
| 3 | Technology | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
UnitedHealth
UNH
$281B
| $60.5M | 4.03% | 120,000 -5,000 | -4% | -$2.52M |
|
2
Pfizer
PFE
$141B
| $58.4M | 3.88% | 1,000,000 | – | – |
|
3
Eli Lilly
LLY
$657B
| $47.1M | 3.13% | 170,000 +25,000 | +17% | +$6.93M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $46M | 3.06% | 425,000 -45,000 | -10% | -$4.87M |
|
|
5
Elevance Health
ELV
$71.8B
| $45.8M | 3.04% | 98,000 -22,000 | -18% | -$10.3M |
|
6
AbbVie
ABBV
$372B
| $45.5M | 3.03% | 335,000 -20,000 | -6% | -$2.72M |
|
7
McKesson
MCK
$85.4B
| $44.1M | 2.93% | 177,000 +29,000 | +20% | +$7.22M |
|
8
Johnson & Johnson
JNJ
$427B
| $43.6M | 2.9% | 253,000 -17,000 | -6% | -$2.93M |
|
9
CVS Health
CVS
$92.8B
| $42.5M | 2.83% | 410,000 +10,000 | +3% | +$1.04M |
|
|
10
Boston Scientific
BSX
$156B
| $39.1M | 2.6% | 910,000 +340,000 | +60% | +$14.6M |
|
11
Jazz Pharmaceuticals
JAZZ
$7.75B
| $37.2M | 2.47% | 290,000 +10,000 | +4% | +$1.28M |
|
12
Vertex Pharmaceuticals
VRTX
$100B
| $36.7M | 2.44% | 165,000 | – | – |
|
13
Cigna
CI
$80.3B
| $32.3M | 2.15% | 140,000 +13,000 | +10% | +$3M |
|
14
Medtronic
MDT
$119B
| $30.9M | 2.06% | 296,000 +23,000 | +8% | +$2.4M |
|
|
15
Alnylam Pharmaceuticals
ALNY
$58.5B
| $29.9M | 1.99% | 175,000 +75,000 | +75% | +$12.8M |
|
|
16
Thermo Fisher Scientific
TMO
$186B
| $29.3M | 1.95% | 44,000 -16,000 | -27% | -$10.6M |
|
17
Cencora
COR
$56.5B
| $29.2M | 1.94% | 218,000 +30,000 | +16% | +$4.01M |
|
|
18
Biogen
BIIB
$19.4B
| $27.6M | 1.84% | 115,000 -35,000 | -23% | -$8.4M |
|
19
Humana
HUM
$36.5B
| $25.6M | 1.71% | 55,000 -2,000 | -4% | -$933K |
|
20
BioMarin Pharmaceuticals
BMRN
$11.2B
| $23.6M | 1.57% | 265,000 +25,000 | +10% | +$2.23M |
|
21
Merck
MRK
$210B
| $23.1M | 1.54% | 300,000 | – | – |
|
22
Becton Dickinson
BDX
$55.3B
| $23M | 1.53% | 91,000 +33,000 | +57% | +$8.36M |
|
23
Cooper Companies
COO
$13.4B
| $23M | 1.53% | 54,260 +9,260 | +21% | +$3.93M |
|
|
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $22.2M | 1.48% | 150,000 | – | – |
|
25
Centene
CNC
$14.3B
| $21.4M | 1.42% | 255,000 -45,000 | -15% | -$3.78M |
|